RMRose G. McHardy

Rose G. McHardy

*This is an algorithmically generated author record based on publicly available information.

Rose G. McHardy has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table S1 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer

    by James M. Cameron, Rose G. McHardy, Alexandra Sala, Holly J. Butler, David S. Palmer, Peter J. Mitchell, Edward Parkin, Susan Moug, Matthew J. Baker

    Supplementary Table S1. Histopathology classification used to assign class labels for the machine learning models.

  • Open Access

    Supplementary Table S2 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer

    by James M. Cameron, Rose G. McHardy, Alexandra Sala, Holly J. Butler, David S. Palmer, Peter J. Mitchell, Edward Parkin, Susan Moug, Matthew J. Baker

    Supplementary Table S2. Additional statistics from an alternative machine learning approach, described in the Methods. Models have been tuned to 90% specificity for the cross-validation.

  • Open Access

    Data from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer

    by James M. Cameron, Rose G. McHardy, Alexandra Sala, Holly J. Butler, David S. Palmer, Peter J. Mitchell, Edward Parkin, Susan Moug, Matthew J. Baker

    Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-based tests and may play a key role in optimizing colorectal cancer detection and diagnostic pathways. In this study, 957 patients were recruited across various clinical sites in the United States: 48 with colorectal cancer, 157 with advanced precancerous lesions (APL), 331 with nonadvanced lesions, and 421 with a negative colonoscopy diagnosis. Blood was obtained from patients either prior to scheduled colonoscopy or before surgical resection and any anticancer therapies. Streck plasma samples were analyzed by the Dxcover Liquid Biopsy Platform and classified using machine learning algorithms. When colorectal cancer was classified against all other groups, the ROC curve generated an AUC value of 0.95, and test sensitivity and specificity were 90% and 89%, respectively. The diagnostic model accurately predicted 75% of stage I (3/4), 100% of stage II (15/15), 93% of stage III (14/15), and 100% of stage IV (6/6) colorectal cancers. For the advanced colorectal neoplasia model, 29% of APL were detected. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.Prevention Relevance:Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.

  • Open Access

    Supplementary Figure S2 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer

    by James M. Cameron, Rose G. McHardy, Alexandra Sala, Holly J. Butler, David S. Palmer, Peter J. Mitchell, Edward Parkin, Susan Moug, Matthew J. Baker

    Supplementary Figure S2. The mean receiver operating characteristic curve for the advanced colorectal neoplasia model, showing the trade-off between sensitivity (Sens) and specificity (Spec). AUC denotes the area under the curve.

  • Open Access

    Supplementary Figure S3 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer

    by James M. Cameron, Rose G. McHardy, Alexandra Sala, Holly J. Butler, David S. Palmer, Peter J. Mitchell, Edward Parkin, Susan Moug, Matthew J. Baker

    Supplementary Figure S3. Relationship between specificity and APL sensitivity for the advanced colorectal neoplasia model.

  • Open Access

    Supplementary Figure S1 from A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer

    by James M. Cameron, Rose G. McHardy, Alexandra Sala, Holly J. Butler, David S. Palmer, Peter J. Mitchell, Edward Parkin, Susan Moug, Matthew J. Baker

    Supplementary Figure S1. Flow diagram illustrating the data analysis process, detailing the cross-validation approach used to report model performance.

  • Open Access

    A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer

    by James M. Cameron, Rose G. McHardy, Alexandra Sala, Holly J. Butler, David S. Palmer, Peter J. Mitchell, Edward Parkin, Susan Moug, Matthew J. Baker

    Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-based tests and may play a key role in optimizing colorectal cancer detection and diagnostic pathways. In this study, 957 patients were recruited across various clinical sites in the United States: 48 with colorectal cancer, 157 with advanced precancerous lesions (APL), 331 with nonadvanced lesions, and 421 with a negative colonoscopy diagnosis. Blood was obtained from patients either prior to scheduled colonoscopy or before surgical resection and any anticancer therapies. Streck plasma samples were analyzed by the Dxcover Liquid Biopsy Platform and classified using machine learning algorithms. When colorectal cancer was classified against all other groups, the ROC curve generated an AUC value of 0.95, and test sensitivity and specificity were 90% and 89%, respectively. The diagnostic model accurately predicted 75% of stage I (3/4), 100% of stage II (15/15), 93% of stage III (14/15), and 100% of stage IV (6/6) colorectal cancers. For the advanced colorectal neoplasia model, 29% of APL were detected. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer. Prevention Relevance: Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.